Innovent Biologics

CompanyChinaROR

Innovent Biologics develops one asset, in phase 2 (Sintilimab in diffuse large B-cell lymphoma). Mostly antibody acting on PDCD1; based in China.

Assets
1
Furthest
Phase 2
Trials
17
Signals
2

Pipeline

1

  • Sintilimab

    Monoclonal antibody targeting PD-1 to block interaction with PD-L1 and PD-L2

    Phase 2AntibodyPDCD1diffuse large B-cell lymphoma

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials24
  • Signals2
  • Similar companies6

Updated 7 Oct 2026 · 27 sources

Intelligence